69 results match your criteria: "Princess Paola Hospital[Affiliation]"
Cartilage
November 2024
MusculoSKeletal Innovative research Lab, CHU Sart-Tilman, Liège, Belgium.
Objectives: Viscosupplementation with hyaluronic acid (HA) is a commonly used intra-articular treatment for osteoarthritis (OA). We performed a Delphi consensus process to formulate guidelines for the use of intra-articular hyaluronic acid (IAHA) knee injection according to the patient's characteristics.
Methods: The EUROVISCO group consists of 12 members who had expertise in clinical and/or research in the field of OA and IAHA treatment.
Osteoarthr Cartil Open
December 2023
NBCD A/S, Herlev, Denmark.
Objective: Arthritic cartilage is primed for mechanical damage. Joint biochemical markers (JBM) could provide insight into the impact of mechanical stimulation on joint tissue turnover in osteoarthritis (OA) of potential use in clinical OA research and practice. However, existing studies of the acute impact of physical activities (PA) on JBM often contain risks of substantial bias.
View Article and Find Full Text PDFBone Res
September 2023
MusculoSKeletal Innovative Research Lab, Center for Interdisciplinary Research on Medicines, Université de Liège, Liège, Belgium.
Abnormal subchondral bone remodeling leading to sclerosis is a main feature of osteoarthritis (OA), and osteomodulin (OMD), a proteoglycan involved in extracellular matrix mineralization, is associated with the sclerotic phenotype. However, the functions of OMD remain poorly understood, specifically in vivo. We used Omd knockout and overexpressing male mice and mutant zebrafish to study its roles in bone and cartilage metabolism and in the development of OA.
View Article and Find Full Text PDFFront Med (Lausanne)
April 2023
Artialis S.A., Liège, Belgium.
Objective: Osteoarthritis (OA) is the most common degenerative joint disease, characterized by a progressive loss of cartilage associated with synovitis and subchondral bone remodeling. There is however no treatment to cure or delay the progression of OA. The objective of this manuscript was to provide a scoping review of the preclinical and clinical studies reporting the effect of gene therapies for OA.
View Article and Find Full Text PDFFront Med (Lausanne)
March 2023
Akasaka Sanno Medical Center, Tokyo, Japan.
[This corrects the article DOI: 10.3389/fmed.2023.
View Article and Find Full Text PDFFront Med (Lausanne)
February 2023
Akasaka Sanno Medical Center, Tokyo, Japan.
Musculoskeletal Care
June 2023
Primary Care Centre Versus Arthritis, School of Medicine, David Weatherall Building, Keele University, Staffordshire, UK.
Pharm Biol
December 2022
Center of Biostatistics (B-STAT), University Hospital of Liège, Liège, Belgium.
Context: Osteoarthritis (OA) of the hand is a common painful musculoskeletal disorder with no cure. There is a need for an efficient and safe treatment to relieve OA pain.
Objective: To investigate the effects of a and food supplement in addition to standard care on hand pain.
Osteoarthritis Cartilage
March 2023
Centre for Health, Exercise & Sports Medicine, Department of Physiotherapy, University of Melbourne, Australia. Electronic address:
Objective: To develop evidence-informed recommendations to support the delivery of best practice therapeutic exercise for people with knee and/or hip osteoarthritis (OA).
Design: A multi-stage, evidence-informed, international multi-disciplinary consensus process that included: 1) a narrative literature review to synthesise existing evidence; 2) generation of evidence-informed proposition statements about delivery of exercise for people with knee and/or hip OA by an international multi-disciplinary expert panel, with statements refined and analysed thematically; 3) an e-Delphi survey with the expert panel to gain consensus on the most important statements; 4) a final round of statement refinement and thematic analysis to group remaining statements into domains.
Results: The expert panel included 318 members (academics, health care professionals and exercise providers, patient representatives) from 43 countries.
Front Pharmacol
August 2022
MusculoSKeletal Innovative Research Lab, Center for Interdisciplinary Research on Medicines, University of Liège, Liège, Belgium.
(CL) and (BS) extracts are used to relieve osteoarthritis symptoms. The aim of this study was to investigate their mechanisms of action at therapeutic plasmatic concentrations on primary human osteoarthritic (OA) chondrocytes. BS (10-50 μg/ml) and CL (0.
View Article and Find Full Text PDFRheumatol Ther
October 2022
Institute of Neurological Sciences IFNAP, Nordostpark 51, 90411, Nuremberg, Germany.
Osteoarthritis is the most common joint disorder affecting over 300 million people worldwide. It typically affects the knees and the hips, and is characterized by a loss in normal joint movement, stiffness, swelling, and pain in patients. The current gold standard therapy for osteoarthritis targets pain management using nonsteroidal anti-inflammatory drugs (NSAIDs).
View Article and Find Full Text PDFBMC Musculoskelet Disord
July 2022
Atlantia Clinical Trials, Heron House Offices, Blackpool, T23 R50R, Cork, Ireland.
Background: Osteoarthritis (OA) is the most frequent cause of disability in elderly people. In daily practice, the main objective of the physician is to reduce patient symptoms using treatments without adverse effects. However, the most prescribed treatment to manage OA symptoms remains nonsteroidal anti-inflammatory drugs which are associated with severe adverse effects.
View Article and Find Full Text PDFJ Endovasc Ther
December 2023
Department of Geriatric Care and Internal Medicine, Princess Paola Hospital, Vivalia, Marche-en-Famenne, Belgium.
Background: To assess the clinical effects of diabetic peripheral neuropathy (DPN) in patients with chronic limb-threatening ischemia (CLTI) treated by primary infrapopliteal angioplasty for neuro-ischemic Rutherford 5, foot wounds.
Materials And Methods: Over a 10-year period (2009-2019), a series of 304 diabetic ischemic limbs adding or not evincible neuropathic affectation were treated by primary infrapopliteal angioplasty and their files were retrospectively reviewed. Mean length of treated arterial lesions was 6.
Front Pharmacol
January 2022
MusculoSKeletal Innovative Research Lab, Center for Interdisciplinary Research on Medicines, University of Liège, Liège, Belgium.
Avocado/soybean unsaponifiables (ASUs) are commonly used to treat OA symptoms. However, there are many ASU mixtures on the market with differing compositions and pharmacological activities. This study aimed to compare the composition and pharmacological activity of seven commercially available ASU products on human osteoarthritis chondrocytes.
View Article and Find Full Text PDFTher Adv Musculoskelet Dis
January 2022
musculoSKeletal Innovative research Lab (mSKIL), The Center for Interdisciplinary Research on Medicines (CIRM), Department of Motricity Center, Institute of Pathology, University of Liège, CHU Sart-Tilman, 4000 Liège, Belgium; Artialis SA, CHU Sart-Tilman, Liège, Belgium; Department of Physical Therapy and Rehabilitation, Princess Paola Hospital, Vivalia, Marche-en-Fammenne, Belgium.
Objectives: To investigate a 6-month intervention with an olive leaf extract (OLE) on knee functionality and biomarkers of bone/cartilage metabolism and inflammation.
Design: This randomized, double-blind, placebo-controlled, multi-centric trial included 124 subjects with knee pain or mobility issues. Subjects received twice a day one capsule of placebo or 125 mg OLE (Bonolive, an OLE containing 50 mg of oleuropein) for 6 months.
Osteoarthritis Cartilage
February 2022
musculoSKeletal Innovative research Lab (mSKIL), Institute of Pathology, Level 5, CHU Sart-Tilman, Center for Interdisciplinary Research on Medicines (CIRM), Department of Motricity Sciences, University of Liège, Belgium; Department of Physical Therapy and Rehabilitation, Princess Paola Hospital, Vivalia, Marche-en-Famenne, Belgium. Electronic address:
Objective: To summarize recent scientific advances in protein-derived soluble biomarkers of osteoarthritis.
Design: A systematic search on the PubMed electronic database of clinical studies on protein-derived soluble biochemical markers of osteoarthritis in humans that were published between January 1st 2020 and March 31th 2021. The studies were selected on the basis of objective criteria and summarized in a table.
Ann Vasc Surg
April 2022
Department of Geriatric care, Princess Paola Hospital Marche-en-Famenne, IFAC/Vivalia, Marche-en-Famenne, Belgium. Electronic address:
Purpose: To assess a specific classification of the foot atherosclerotic disease concerning the angiosomal source arteries, the connected foot arches and attached collaterals for Rutherford 5, CLTI patients. To compare eventual analogies of this novel grading system with previously reported GLASS/GVG inframalleolar patterns of occlusive disease (P0-P2).
Materials And Methods: A series of 336 ischemic feet (221 diabetics) were selected and retrospectively analyzed.
Front Med (Lausanne)
July 2021
Department of Internal Medicine, Faculdade de Medicina da Universidade Federal do Ceará, Fortaleza, Brazil.
Food Sci Nutr
June 2021
Abyss Ingredients Caudan France.
The objective of this study was to evaluate the effects of oral fish cartilage hydrolysate (FCH) on symptoms and joint tissue structure in rat developing osteoarthritis induced surgically. Osteoarthritis was induced in the right knee of mature male Lewis rats ( = 12/group) by surgical transection of the anterior cruciate ligament (ACLT) combined with partial medial meniscectomy (pMMx). Two weeks after surgery, rats were treated orally with either control (sterile HO) or FCH for four weeks.
View Article and Find Full Text PDFCartilage
December 2021
ARTIALIS SA, CHU Sart-Tilman, Liège, Belgium.
Objective: To assess the cross-sectional association between serum levels of Coll2-1 and Coll2-1NO2, two cartilage degradation biomarkers; the burden of magnetic resonance imaging (MRI) features and clinical outcomes; and to evaluate the predictive value of these biomarkers on progression.
Design: A total of 121 subjects with knee osteoarthritis (OA) were followed during 1 year with pain, function, and MRI assessment (PRODIGE study). Type II collagen-specific biomarker Coll2-1 and its nitrated form Coll2-1NO2 were directly measured in serum using immunoassays at baseline and after 3-, 6-, and 12-month follow-up.
Front Pharmacol
May 2021
MusculoSKeletal Innovative Research Lab, University of Liège, Center for Interdisciplinary Research on Medicines, Liège, Belgium.
Zeel T (Ze14) is a multicomponent medicinal product. Initial preclinical data suggested a preventive effect on cartilage degradation. Clinical observational studies demonstrated that Ze14 reduced symptoms of osteoarthritis (OA), including stiffness and pain.
View Article and Find Full Text PDFFront Med (Lausanne)
January 2021
MusculoSKeletal Innovative Research Lab, University of Liège, Institute of Pathology, CHU Sart-Tilman, Liège, Belgium.
During the osteoarthritis (OA) process, activation of immune systems, whether innate or adaptive, is strongly associated with low-grade systemic inflammation. This process is initiated and driven in the synovial membrane, especially by synovium cells, themselves previously activated by damage-associated molecular patterns (DAMPs) released during cartilage degradation. These fragments exert their biological activities through pattern recognition receptors (PRRs) that, as a consequence, induce the activation of signaling pathways and beyond the release of inflammatory mediators, the latter contributing to the vicious cycle between cartilage and synovial membrane.
View Article and Find Full Text PDFCurr Med Res Opin
March 2021
Department of Biostatistics, University Hospital of Liège, Liège, Belgium.
To investigate the effects of 1-month treatment in addition to standard care with a food supplement containing both and extracts on tendinopathy symptoms. This open-label, non-controlled, post-observational study included 670 patients suffering from tendinopathy recruited at different sites by Belgian general practitioners. Patients received a medical prescription for 1-month treatment with two tablets twice a day of a pharmaceutical grade food supplement containing both and extracts.
View Article and Find Full Text PDFArthritis Care Res (Hoboken)
December 2021
University of Melbourne, Victoria, Australia.
Therapeutic exercise is a recommended first-line treatment for patients with knee and hip osteoarthritis (OA); however, there is little specific advice or practical resources to guide clinicians in its implementation. As the first in a series of projects by the Osteoarthritis Research Society International Rehabilitation Discussion Group to address this gap, we aim in this narrative review to synthesize current literature informing the implementation of therapeutic exercise for patients with knee and hip OA, focusing on evidence from systematic reviews and randomized controlled trials. Therapeutic exercise is safe for patients with knee and hip OA.
View Article and Find Full Text PDF